Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Stem Cell Research

  Free Subscription

Articles published in Leuk Lymphoma

Retrieve available abstracts of 63 articles:
HTML format

Single Articles

    August 2022
  1. TARANTO E, Redd R, Jeter E, McHugh K, et al
    Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2022 Aug 7:1-6. doi: 10.1080/10428194.2022.2103808.
    PubMed     Abstract available

    July 2022
  2. LOLLI G, Ursi M, Dicataldo M, Casadei B, et al
    Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient.
    Leuk Lymphoma. 2022 Jul 22:1-3. doi: 10.1080/10428194.2022.2102622.

  3. ZAMA D, Mondardini MC, Petris MG, Amigoni A, et al
    Pediatric cancer and hematopoietic stem cell transplantation patients requiring renal replacement therapy: results of the retrospective nationwide AIEOP study.
    Leuk Lymphoma. 2022 Jul 12:1-8. doi: 10.1080/10428194.2022.2095628.
    PubMed     Abstract available

    June 2022
  4. SERPENTI F, Sciume M, Galassi G, Saporiti G, et al
    Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse.
    Leuk Lymphoma. 2022 Jun 22:1-4. doi: 10.1080/10428194.2022.2090553.

  5. LIU Y, Qi L, Wang T, Zhou B, et al
    The clinical outcomes of mixed engraftment patients treated with haploidentical stem cells combined with umbilical cord blood transplantation.
    Leuk Lymphoma. 2022 Jun 18:1-5. doi: 10.1080/10428194.2022.2086245.

  6. HO M, Moscvin M, Low SK, Evans B, et al
    Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma.
    Leuk Lymphoma. 2022 Jun 14:1-10. doi: 10.1080/10428194.2022.2084729.
    PubMed     Abstract available

  7. LAHOUD OB, Landau H, Nguyen J, Devlin S, et al
    Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach.
    Leuk Lymphoma. 2022 Jun 1:1-10. doi: 10.1080/10428194.2022.2062347.
    PubMed     Abstract available

    May 2022
  8. HOWELLS L, Chan WY, Sanchez E, Horder J, et al
    Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination.
    Leuk Lymphoma. 2022 May 14:1-5. doi: 10.1080/10428194.2022.2074989.

  9. GERTZ MA, Warsame R, Muchtar E, Buadi F, et al
    Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2022 May 12:1-6. doi: 10.1080/10428194.2022.2074993.
    PubMed     Abstract available

    April 2022
  10. PORRATA LF, Inwards DJ, Ansell SM, Micallef IN, et al
    Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.
    Leuk Lymphoma. 2022 Apr 28:1-8. doi: 10.1080/10428194.2022.2064988.
    PubMed     Abstract available

  11. TAMAKI M, Nakasone H, Nakamura Y, Kawamura M, et al
    Risk factors and outcomes of definite or clinical idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2022 Apr 7:1-9. doi: 10.1080/10428194.2022.2057486.
    PubMed     Abstract available

    March 2022
  12. PERKINS B, Showel M, Schoch L, Imus PH, et al
    CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 27:1-7. doi: 10.1080/10428194.2022.2038375.
    PubMed     Abstract available

    February 2022
  13. MUKHERJEE A, Milton DR, Jabbour EJ, Gulbis AM, et al
    Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.
    Leuk Lymphoma. 2022 Feb 27:1-9. doi: 10.1080/10428194.2022.2043302.
    PubMed     Abstract available

  14. KAMADA Y, Arima N, Hayashida M, Nakamura D, et al
    Prediction of the risk for graft versus host disease after allogeneic hematopoietic stem cell transplantation in patients treated with mogamulizumab.
    Leuk Lymphoma. 2022 Feb 27:1-7. doi: 10.1080/10428194.2022.2043300.
    PubMed     Abstract available

  15. NAGAYAMA T, Fujiwara SI, Kikuchi T, Onda K, et al
    Impact of muscle mass loss assessed by computed tomography on the outcome of allogeneic stem cell transplantation.
    Leuk Lymphoma. 2022 Feb 14:1-7. doi: 10.1080/10428194.2022.2034159.
    PubMed     Abstract available

    January 2022
  16. WANG SSY
    Relationship between leukaemic stem cells and hematopoietic stem cells and their clinical application.
    Leuk Lymphoma. 2022 Jan 22:1-10. doi: 10.1080/10428194.2022.2027401.
    PubMed     Abstract available

  17. IKEDA D, Tsushima T, Fukumoto A, Kuzume A, et al
    Rapid liver atrophy and refractory ascites due to hepatoportal sclerosis in a patient after haploidentical stem cell transplantation.
    Leuk Lymphoma. 2022 Jan 12:1-4. doi: 10.1080/10428194.2022.2027400.

    December 2021
  18. LU Y, Zhao YL, Xiong M, Sun RJ, et al
    Unmanipulated haploidentical donor and matched unrelated donor hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: a single-center study.
    Leuk Lymphoma. 2021 Dec 16:1-9. doi: 10.1080/10428194.2021.2015588.
    PubMed     Abstract available

  19. SINGH V, Kim S, Deol A, Uberti JP, et al
    Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: a Meta-Analysis.
    Leuk Lymphoma. 2021 Dec 5:1-10. doi: 10.1080/10428194.2021.1999438.
    PubMed     Abstract available

    November 2021
  20. PALMIERI R, Buccisano F, Arena V, Irno Consalvo MA, et al
    CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia.
    Leuk Lymphoma. 2021 Nov 21:1-5. doi: 10.1080/10428194.2021.2005042.

  21. HOSOI H, Matsuyama Y, Murata S, Mushino T, et al
    Prolonged Epstein-Barr virus reactivation coincident with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 Nov 16:1-4. doi: 10.1080/10428194.2021.2005047.

  22. JADERSTEN M, Boriskina K, Lindholm C, Westrom S, et al
    Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Nov 15:1-4. doi: 10.1080/10428194.2021.2002319.

  23. SOARE DS, Radu E, Dumitru I, Vladareanu AM, et al
    Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations.
    Leuk Lymphoma. 2021;62:2716-2726.
    PubMed     Abstract available

    October 2021
  24. ALHOMOUD M, Williams A, Magro C, Van Besien K, et al
    Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults.
    Leuk Lymphoma. 2021 Oct 20:1-5. doi: 10.1080/10428194.2021.1992625.

  25. ARCARI A, Morello L, Vallisa D, Marcheselli L, et al
    Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi.
    Leuk Lymphoma. 2021 Oct 8:1-10. doi: 10.1080/10428194.2021.1961238.
    PubMed     Abstract available

  26. KOO RM, Ritchie D
    Self-reliance or the generosity of others?: autologous versus allogeneic stem cell transplantation in high-risk Hodgkin lymphoma.
    Leuk Lymphoma. 2021;62:2303-2305.

    September 2021
  27. PAVIGLIANITI A, Sestili S, Bianchessi A, Memoli M, et al
    Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience.
    Leuk Lymphoma. 2021 Sep 29:1-7. doi: 10.1080/10428194.2021.1984460.
    PubMed     Abstract available

  28. SAWALHA Y, Radivoyevitch T, Jia X, Tullio K, et al
    The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma.
    Leuk Lymphoma. 2021 Sep 15:1-9. doi: 10.1080/10428194.2021.1978085.
    PubMed     Abstract available

    August 2021
  29. PATEL SA, Dalela D, Fan AC, Lloyd MR, et al
    Niche-directed therapy in acute myeloid leukemia: optimization of stem cell competition for niche occupancy.
    Leuk Lymphoma. 2021 Aug 19:1-9. doi: 10.1080/10428194.2021.1966779.
    PubMed     Abstract available

  30. WANG J, Yang L, Dao FT, Wang YZ, et al
    Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia.
    Leuk Lymphoma. 2021 Aug 18:1-10. doi: 10.1080/10428194.2021.1966785.
    PubMed     Abstract available

  31. DROZD-SOKOLOWSKA J, Waszczuk-Gajda A, Biecek P, Kobylinska K, et al
    Salvage autologous hematopoietic stem cell transplantation for multiple myeloma performed with stem cells procured after previous high dose therapy - a multicenter report by the Polish Myeloma Study Group.
    Leuk Lymphoma. 2021 Aug 16:1-9. doi: 10.1080/10428194.2021.1950712.
    PubMed     Abstract available

  32. RICHARDS H, Chavda SJ, Wilson W, Camilleri M, et al
    Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-center UK experience.
    Leuk Lymphoma. 2021 Aug 4:1-4. doi: 10.1080/10428194.2021.1961240.

    July 2021
  33. ENSSLE JC, Wolf S, von Metzler I, Weber S, et al
    High CD34 positive stem cell dosage improves thrombocyte recovery in obese myeloma patients undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2021 Jul 13:1-5. doi: 10.1080/10428194.2021.1950707.

    June 2021
  34. CAMILLERI M, McGrath T, Wilson W, Ings SJ, et al
    Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patients.
    Leuk Lymphoma. 2021 Jun 24:1-4. doi: 10.1080/10428194.2021.1941930.

  35. YOSHIMOTO G, Mori Y, Kato K, Odawara J, et al
    Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Jun 23:1-10. doi: 10.1080/10428194.2021.1941937.
    PubMed     Abstract available

  36. HUSBY S, Favero F, Rodriguez-Gonzalez FG, Sutton LA, et al
    Mutations known from B-cell lymphoid malignancies are not found in CD34(+) stem cells from patients with lymphoma.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1933473.

  37. ZAMAGNI E, Dhanasiri S, Ghale A, Moore A, et al
    Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-b
    Leuk Lymphoma. 2021 Jun 14:1-10. doi: 10.1080/10428194.2021.1924369.
    PubMed     Abstract available

    May 2021
  38. PASVOLSKY O, Shargian L, Rozovski U, Wolach O, et al
    Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation.
    Leuk Lymphoma. 2021 May 20:1-8. doi: 10.1080/10428194.2021.1929957.
    PubMed     Abstract available

  39. LIANG D, Wei C, Zhang X, Yang J, et al
    Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 May 17:1-5. doi: 10.1080/10428194.2021.1919665.

  40. KUROSAWA S, Kaito S, Uchida N, Fukuda T, et al
    Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study.
    Leuk Lymphoma. 2021 May 12:1-7. doi: 10.1080/10428194.2021.1924374.
    PubMed     Abstract available

    March 2021
  41. EPSTEIN-PETERSON ZD, Ganesan N, Barker JN, Drullinsky PR, et al
    Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience.
    Leuk Lymphoma. 2021 Mar 29:1-7. doi: 10.1080/10428194.2021.1897806.
    PubMed     Abstract available

  42. WENGE DV, Wethmar K, Mikesch JH, Reicherts C, et al
    Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy.
    Leuk Lymphoma. 2021 Mar 29:1-10. doi: 10.1080/10428194.2021.1894645.
    PubMed     Abstract available

  43. CAZELLES C, Belhadj K, Vellemans H, Camus V, et al
    Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
    Leuk Lymphoma. 2021 Mar 25:1-8. doi: 10.1080/10428194.2021.1901090.
    PubMed     Abstract available

  44. FULCHER J, Berardi P, Christou G, Villeneuve PJA, et al
    Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Mar 21:1-3. doi: 10.1080/10428194.2021.1901097.

  45. SHEN Y, Qi J, Wang Y, Chen J, et al
    Hepatitis B immunoglobulin (HBIG) combined with long-term entecavir prophylaxis for hepatitis B virus infection in allogeneic hematopoietic stem cell transplantation with hepatitis B surface antigen-positive donors.
    Leuk Lymphoma. 2021 Mar 18:1-4. doi: 10.1080/10428194.2021.1901095.

    February 2021
  46. MODI D, Albanyan O, Kim S, Deol A, et al
    Grade 3-4 cytokine release syndrome is associated with poor survival in haploidentical peripheral blood stem cell transplantation.
    Leuk Lymphoma. 2021 Feb 24:1-11. doi: 10.1080/10428194.2021.1891231.
    PubMed     Abstract available

    January 2021
  47. PRABAHRAN A, Koldej R, Chee L, Wong E, et al
    Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Jan 31:1-13. doi: 10.1080/10428194.2021.1872072.
    PubMed     Abstract available

  48. JAIME-PEREZ JC, Hernandez-Coronado M, Picon-Galindo E, Salazar-Cavazos L, et al
    Results of a completely outpatient autologous stem cell transplant program for lymphoma patients receiving reduced-intensity conditioning.
    Leuk Lymphoma. 2021 Jan 24:1-10. doi: 10.1080/10428194.2021.1876870.
    PubMed     Abstract available

    December 2020
  49. PLATE M, van Besien K
    Is less more? Viewpoint on empiric vancomycin therapy of fever and neutropenia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2020 Dec 27:1-3. doi: 10.1080/10428194.2020.1864357.

  50. MORIGI A, Casadei B, Argnani L, Stefoni V, et al
    Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma.
    Leuk Lymphoma. 2020 Dec 4:1-3. doi: 10.1080/10428194.2020.1855342.

    November 2020
  51. VOCKOVA P, Molinsky J, Klanova M, Karban J, et al
    CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement.
    Leuk Lymphoma. 2020 Nov 25:1-8. doi: 10.1080/10428194.2020.1849678.
    PubMed     Abstract available

  52. RASOR B, Dickerson T, Zhao Q, Elder P, et al
    Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
    Leuk Lymphoma. 2020 Nov 24:1-10. doi: 10.1080/10428194.2020.1849677.
    PubMed     Abstract available

  53. WANG T, Zhou B, Zhang J, Zhang X, et al
    Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation.
    Leuk Lymphoma. 2020 Nov 16:1-4. doi: 10.1080/10428194.2020.1846736.
    PubMed     Abstract available

  54. FU W, Huang A, Lu G, Ni X, et al
    Value of pre-transplant consolidation chemotherapy in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation without minimal residual disease in first complete remission.
    Leuk Lymphoma. 2020 Nov 11:1-8. doi: 10.1080/10428194.2020.1845340.
    PubMed     Abstract available

  55. GAUT D, Mead M
    Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies.
    Leuk Lymphoma. 2020 Nov 2:1-24. doi: 10.1080/10428194.2020.1827251.
    PubMed     Abstract available

  56. ABBOUD R, Slade M, Abboud C, DiPersio JF, et al
    Can planned CD34+ stem cell boost prevent poor graft function after peripheral blood haploidentical hematopoietic transplantation?
    Leuk Lymphoma. 2020 Nov 2:1-3. doi: 10.1080/10428194.2020.1839657.

  57. PAN W, Zhao X, Shi W, Jiang Z, et al
    Venetoclax induced complete remission in extramedullary relapse of AML co-harboring NPM1, TET2, and NRAS mutations after haploidentical hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2020;61:2756-2759.

    October 2020
  58. LIU W, Wu M, Xie Y, Zhang C, et al
    Autologous hematopoietic stem cell transplantation with inadequate stem cell dose in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 15:1-7. doi: 10.1080/10428194.2020.1834092.
    PubMed     Abstract available

  59. SINGH V, Jang H, Kim S, Ayash L, et al
    G-CSF use post peripheral blood stem cell transplant is associated with faster neutrophil engraftment, shorter hospital stay and increased incidence of chronic GVHD.
    Leuk Lymphoma. 2020 Oct 12:1-8. doi: 10.1080/10428194.2020.1827244.
    PubMed     Abstract available

  60. HEINICKE T, Labopin M, Polge E, Stelljes M, et al
    Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT.
    Leuk Lymphoma. 2020 Oct 11:1-11. doi: 10.1080/10428194.2020.1827248.
    PubMed     Abstract available

  61. MOUNTJOY L, Palmer J, Kunze KL, Khera N, et al
    Does early chimerism testing predict outcomes after allogeneic hematopoietic stem cell transplantation?
    Leuk Lymphoma. 2020 Oct 4:1-3. doi: 10.1080/10428194.2020.1827249.

    September 2020
  62. LADHA A, Mannis G, Muffly L
    Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin.
    Leuk Lymphoma. 2020 Sep 29:1-7. doi: 10.1080/10428194.2020.1827247.
    PubMed     Abstract available

  63. TATARCZUCH M, Paul E, Gilberston M, Gregory GP, et al
    Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy.
    Leuk Lymphoma. 2020 Sep 27:1-6. doi: 10.1080/10428194.2020.1821007.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Stem Cell Research is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.